CN106389589A - Medicine with effect of relieving cough and reducing sputum - Google Patents
Medicine with effect of relieving cough and reducing sputum Download PDFInfo
- Publication number
- CN106389589A CN106389589A CN201611028907.4A CN201611028907A CN106389589A CN 106389589 A CN106389589 A CN 106389589A CN 201611028907 A CN201611028907 A CN 201611028907A CN 106389589 A CN106389589 A CN 106389589A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- cough
- fructus
- sandwort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a medicine with an effect of relieving cough and reducing sputum. The medicine is prepared from an active ingredient or the active ingredient and pharmaceutically acceptable adjuvant materials, wherein the active ingredient is prepared from sandwort, eriophyton wallichii benth, rose flower, phlomis younghusbandii, asteris souliei, medicago ruthenica, licorice root, costus root, fructus hippophais, and fructus chebulae according to a certain weight proportion. The medicine can be prepared into any common internal dosage form. The medicine disclosed by the invention has the effects of relieving cough, reducing sputum and clearing throat, and is used for treating cough, vomiturition, thick viscous phlegm and excessive phlegm, and the like.
Description
Technical field
The present invention relates to a kind of medicine with relieving cough and resolving phlegm effect.
Background technology
Respiratory system disease cardinal symptom be cough, expectorant, breathe heavily, scorching, be one of high morbidity in the world today, account for internal disease
1/4, its mortality rate accounts for the 3rd in city, ranks first in rural area.The mouth of the development with aged tendency of population and atmospheric pollution becomes tight
Weight, respiratory system disease occurs in rising trend.
Cough is most commonly seen disease in Medicine disease, and sickness rate is high, and exogenous cough is due to diseases caused by exogenous pathogenic factor six climate exopathogens, causes lung
Gas is unclear, loses respectful caused in declaring, to cough, to cough up phlegm as the disease of main performance.
Up to now, also do not find any report about pharmaceutical composition of the present invention.As a result of repeated studies by the present inventors,
And the checking repeatedly by animal and clinical trial, finally have found the oral drugs of more preferable relieving cough and resolving phlegm curative effect, thus complete
Become the present invention.
Content of the invention
The object of the invention is exactly to provide a kind of oral drugs having more preferable relieving cough and resolving phlegm curative effect.
The present invention is a kind of pharmaceutical composition, is to be made up of active component or by active component and pharmaceutically acceptable
Adjuvant make, wherein said active component is made up of following bulk drugs：Sandwort, Eriophyton wallichii Benth, the Flos rosae multiflorae, Radix phlomidis younghusbandii, Tibetan are purple
Aster, Herba Trigonellae Ruthenicae, Radix Glycyrrhizae, the Radix Aucklandiae, Fructus Hippophae extractum, Fructus Chebulae.
It has selected sandwort, Eriophyton wallichii Benth, the Flos rosae multiflorae, Radix phlomidis younghusbandii, hides Radix Asteriss, Herba Trigonellae Ruthenicae, Radix Glycyrrhizae, the Radix Aucklandiae, Fructus Hippophae extractum, He Zijin
Row combination as raw material, wherein（1）Sandwort is pinkwort Gansu sandwort Arenaria Kansuensis Maxim. and ovum
The herb of lobe sandwort Arenaria ka-nsuensis Maxim.var. OvatipetataTsui..Have and bring down a fever, cough-relieving
Effect.For pneumonia and various pneumonopathy.（2）Eriophyton wallichii Benth is the dry of labiate Eriophyton wallichii Benth Eriophyton WallichiiBehth
Dry herb.There is heat-clearing and toxic substances removing, effect of cough-relieving.For influenza, pestilence, hepatitis, pneumonia, pulmonary abscess, pulmonary tuberculosis, lung
Heat cough, infectiousness heat symptom-complex.（3）The Flos rosae multiflorae is rosaceous plant mount emei Flos Rosae Multiflorae Rosa omeiensis Rolfe, tough silk hair rose
Rosa sericea Lindl. is dried petal.There is sending down the abnormal ascending QI clearing gallbladder, effect of promoting blood flow to regulate menstruation.For " imperial " disease, " red bar "
Disease, cough due to lung-heat, spit blood, menoxenia, vascular stasis caused pain, leucorrhea with red and white discharge, acute mastitis etc..（4）Radix phlomidis younghusbandii is labiate Eriocheir sinensiss
The dried root of first Phlomis younghusbandii Mukerjee.There is cold expelling wet one's whistle, effect of torr sore myogenic.For
Baconic's sympotoms caused by cold factors, throat epidemic disease, pneumonopathy, cold cough, bronchitis, long skin ulcer does not heal.（5）Tibetan Radix Asteriss are feverfew green hair Radix Asteriss
Aster souliei Franch is dried inflorescence.There is heat-clearing and toxic substances removing, effect of relieving cough and expelling phlegm.For pestilence, nosotoxicosiss,
Bronchitis, cough and asthma, cough vomiting bloody pus.（6）Herba Trigonellae Ruthenicae is leguminous plant Herba Trigonellae Ruthenicae Trigonella ruthenica L.'s
Herb is dried.There is heat-clearing and toxic substances removing, effect of kidney tonifying more skin ulcer.For sore rash, cough due to lung-heat.（7）Radix Glycyrrhizae is glycyrrhizic legume
Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. Glycyrrhizainflata Bat. or Glycyrrhiza glabra L.
Glycyrrhiza glabra L. is dried root and rhizome.Nature and flavor are sweet, put down；GUIXIN, lung, spleen, stomach.There is invigorating the spleen and replenishing QI, clearly
Thermal detoxification, expelling phlegm for arresting cough, relieving spasm to stop pain, the effect of coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, expectorant of coughing
Many, gastral cavity abdomen, four limbs contraction, carbuncle sore tumefacting virus, alleviate drug toxicity, strong.There is arrhythmia, antiulcer, suppression stomach
Acid secretion, alleviate gastrointestinal smooth muscular spasm and analgesia, promote pancreatic secretion, antitussive, eliminating the phlegm, relieving asthma, antibacterial, antiviral, antiinflammatory,
The pharmacological actions such as antiallergic, can protect throat and the tunica mucosa tracheae of inflammation, have the removing toxic substances of similar glucuronic acid to some poisonous substances
Effect, has similar adrenocortical hormone sample effect, the also effect such as diuresiss, lipid-loweringing, liver protection.（8）The Radix Aucklandiae is feverfew
The dry root of Radix Aucklandiae Aucklandia lappaDecne..There is promoting the circulation of QI to relieve pain, effect of strengthening the spleen to promote digestion.For chest gastral cavity distending pain,
Weight after rush down dysentery, dyspepsia, anorexia.（9）Fructus Hippophae extractum is Elaeangnaceae plant Fructus Hippophae Hippophae rhamnoides L.
The herbal decoction of mature fruit.Nature and flavor acid, puts down.There is clearing and antitussive, effect of blood circulation promoting and blood stasis dispelling, more ulcer.For tracheitiies, digest
Bad, the disease such as gastric ulcer and amenorrhea.Have resist myocardial ischemia, anoxia, myocardial cell function of improving, arrhythmia, antitumor,
The pharmacological actions such as the liver protecting and ALT lowering, enhancing immunologic function, antioxidation and slow down aging.（10）Fructus Chebulae is Combretum Racemosum plant Fructus Chebulae
Terminalia Chebula Retz. or Terminalia chebula Retz. var. tomentella Kurt. Terminalia chebulaRetz.var.
The dry mature fruit of tomentella Kurt..There is astringing intestine to stop diarrhea astringe the lung, effect of pathogenic fire reducing sore-throat relieving.For protracted dysentery and diarrhea,
Have blood in stool proctoptosis, the deficiency of the lung is breathed with cough, chronic cough is more than, pharyngalgia hoarseness.These drug regimens are made each efficacy of drugs produce collaborative
Effect, thus have functions that good relieving cough and resolving phlegm.
The consumption of drug component of the present invention is also to be groped in a large number to summarize to draw through inventor, each raw material survival dose
It is, in following concrete weight ranges, all there is good therapeutic effect：Sandwort 35～105g, Eriophyton wallichii Benth 30～90g, the Flos rosae multiflorae 20～60g,
Radix phlomidis younghusbandii 40～120g, Tibetan Radix Asteriss 35～105g, Herba Trigonellae Ruthenicae 20～60g, Radix Glycyrrhizae 10～30g, the Radix Aucklandiae 10～30g, Fructus Hippophae extractum 10
～30g, Fructus Chebulae 25～75g.
It is preferably：Sandwort 56～84g, Eriophyton wallichii Benth 48～72g, the Flos rosae multiflorae 32～48g, Radix phlomidis younghusbandii 64～96g, hide Radix Asteriss 56～
84g, Herba Trigonellae Ruthenicae 32～48g, Radix Glycyrrhizae 16～24g, the Radix Aucklandiae 16～24g, Fructus Hippophae extractum 16～24g, Fructus Chebulae 40～60g.
More preferably：Sandwort 70g, Eriophyton wallichii Benth 60g, Flos rosae multiflorae 40g, Radix phlomidis younghusbandii 80g, hide Radix Asteriss 70g, Herba Trigonellae Ruthenicae 40g,
Radix Glycyrrhizae 20g, Radix Aucklandiae 20g, Fructus Hippophae extractum 20g, Fructus Chebulae 50g.
The preparation of medicine activity component of the present invention can be to pulverize the crude drug convection drying of above-mentioned consumption to make；Also may be used
The crude drug of above-mentioned consumption to be adopted the conventional method such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation of Chinese medicine preparation（Referring to Cao Chunlin
Chief editor's《Pharmaceutics of Chinese drugs》Page 73～74, Science and Technology of Shanghai publishing house in November, 1986 publishes）It is obtained.
The active component of medicine of the present invention can add required various customary adjuvant when preparing different dosage form, such as disintegrate
Agent, lubricant, binding agent etc. are with conventional method of Chinese medicinal（Referring to Cao Chunlin chief editor's《Pharmaceutics of Chinese drugs》, Science and Technology of Shanghai
Publishing house's in November, 1986 publishes）It is prepared into any conventional peroral dosage form, such as decoction pulvis, medicinal tea, powder, pill, capsule
Agent, granule, tablet etc..
Medicine of the present invention has functions that relieving cough and resolving phlegm, pharynx-clearing throat-benefiting.For coughing, retching, the thick abundant expectoration of expectorant etc..
【Specific embodiment】
The preparation method of of the present invention medicine is expanded on further by the following examples.
【Embodiment 1】The decoction pulvis preparation of medicine of the present invention：
Weigh sandwort 70g, Eriophyton wallichii Benth 60g, Flos rosae multiflorae 40g, Radix phlomidis younghusbandii 80g, hide Radix Asteriss 70g, Herba Trigonellae Ruthenicae 40g, Radix Glycyrrhizae 20g, the Radix Aucklandiae
20g, Fructus Hippophae extractum 20g, Fructus Chebulae 50g, are ground into coarse powder jointly after mixing, mix, subpackage, obtain final product decoction pulvis.
Usage and dosage is：Put in 150ml water and decoct, when decocting is to 1/3, taking liquid is drunk；3g, 2～3 times on the one.
【Embodiment 2】The medicinal tea preparation of medicine of the present invention：
Weigh sandwort 63g, Eriophyton wallichii Benth 54g, Flos rosae multiflorae 36g, Radix phlomidis younghusbandii 72g, hide Radix Asteriss 63g, Herba Trigonellae Ruthenicae 36g, Radix Glycyrrhizae 18g, the Radix Aucklandiae
18g, Fructus Hippophae extractum 18g, Fructus Chebulae 45g, are ground into coarse powder jointly after mixing, mix, subpackage, obtain final product medicinal tea.
Usage and dosage is：Boiled water brews to be drunk；3g, 2～3 times on the one.
【Embodiment 3】The powder preparation of medicine of the present invention：
Weigh sandwort 56g, Eriophyton wallichii Benth 48g, Flos rosae multiflorae 32g, Radix phlomidis younghusbandii 64g, hide Radix Asteriss 56g, Herba Trigonellae Ruthenicae 32g, Radix Glycyrrhizae 16g, the Radix Aucklandiae
16g, Fructus Hippophae extractum 16g, Fructus Chebulae 40g, are ground into fine powder jointly after mixing, mix, subpackage, obtain final product powder.
Usage and dosage is：Oral；1.2～2g, 2～3 times on the one.
【Embodiment 4】The pill preparation of medicine of the present invention：
Weigh sandwort 84g, Eriophyton wallichii Benth 72g, Flos rosae multiflorae 48g, Radix phlomidis younghusbandii 96g, hide Radix Asteriss 84g, Herba Trigonellae Ruthenicae 48g, Radix Glycyrrhizae 24g, the Radix Aucklandiae
24g, Fructus Hippophae extractum 24g, Fructus Chebulae 60g, are ground into fine powder jointly after mixing, mix, with water pill, be dried, polishing below 60 DEG C,
Packaging, obtains final product pill.
Usage and dosage is：Oral；1.2～2g, 2～3 times on the one.
【Embodiment 5】The granule preparation of medicine of the present invention：
Weigh sandwort 35g, Eriophyton wallichii Benth 30g, Flos rosae multiflorae 20g, Radix phlomidis younghusbandii 40g, hide Radix Asteriss 35g, Herba Trigonellae Ruthenicae 20g, Radix Glycyrrhizae 10g, the Radix Aucklandiae
10g, Fructus Hippophae extractum 10g, Fructus Chebulae 25g, are ground into fine powder jointly after mixing, mix, and add adjuvant to make granule, do below 60 DEG C
Dry, granulate, subpackage, obtain final product granule.
Usage and dosage is：Oral；1.2～2g, 2～3 times on the one.
【Embodiment 6】The capsule preparation of medicine of the present invention：
Weigh sandwort 105g, Eriophyton wallichii Benth 90g, Flos rosae multiflorae 60g, Radix phlomidis younghusbandii 120g, hide Radix Asteriss 105g, Herba Trigonellae Ruthenicae 60g, Radix Glycyrrhizae 30g, wood
Fragrant 30g, Fructus Hippophae extractum 30g, Fructus Chebulae 75g, are ground into fine powder jointly after mixing, mix, and load gelatine capsule, obtain final product capsule.
Usage and dosage is：Oral；1.2～2g, 2～3 times on the one.
【Embodiment 7】The tablet preparation of medicine of the present invention：
Weigh sandwort 47g, Eriophyton wallichii Benth 42g, Flos rosae multiflorae 28g, Radix phlomidis younghusbandii 56g, hide Radix Asteriss 49g, Herba Trigonellae Ruthenicae 28g, Radix Glycyrrhizae 14g, the Radix Aucklandiae
14g, Fructus Hippophae extractum 14g, Fructus Chebulae 35g, are ground into fine powder jointly after mixing, mix, and add adjuvant to make granule, do below 60 DEG C
Dry, granulate, tabletting, obtain final product tablet.
Usage and dosage is：Oral；1.2～2g, 2～3 times on the one.
The beneficial effect of of the present invention medicine is expanded on further below by way of test example, these test examples include the present invention
The pharmacodynamics test of Medications Example 4 and clinical observation on the therapeutic effect test.
【Test example 1】The antitussive of Medications Example 4 of the present invention, eliminating the phlegm, relieving asthma, the test such as antiinflammatory action：
Experimental technique：1st, the antitussive test of Medications Example 4 of the present invention：Take mice 50, male and female half and half, be randomly divided into 5 groups, often
Group 10.I.e. blank control group, to isometric(al) distilled water；Positive controls, to pinellia tuber for relieving cough syrup 15ml/kg.d-l；The present invention
The high, medium and low dosage group of Medications Example 4, gives Medications Example 4 medicine 10g, 5g, 2.5g crude drug/kg.d of the present invention respectively-l.
The equal gastric infusion of each group, 1 time/d, continuous 7 days.After last dose 60min, mice accepts 25% strong aqua ammonia spraying 10s, and observation is coughed
Time and number of times that reaction of coughing occurs, cough number of times in the cough latent period of record mice and 2min.The results are shown in Table 1.
The antitussive action (x ± s, n=10) to mice for table 1 Medications Example 4 of the present invention
Group Animals number dosage (g/kg) cough latent period (s) cough number of times（Secondary）
Blank control group 10 27.5 ± 16.27 51.1 ± 3.65
Positive controls 10 15ml/Kg 46.6 ± 6.77**28.3±6.20**
Low dose group 10 2.5 42.3 ± 19.72*34.6±7.25**
Middle dose group 10 5 47.6 ± 5.34**30.5±6.68**
High dose group 10 10 51.9 ± 3.19**27.6±4.40**
Explanation：Compare with blank control group:*P<0.05；**P<0.0l.
As seen from Table 1：Medications Example 4 of the present invention can effectively suppress the mouse cough of strong aqua ammonia induction, makes coughing of mice
Also make be obviously prolonged the incubation period of mouse cough while number of times of coughing significantly reduces, compare with blank control group, little, in, big agent
Amount group has significant difference（P<0.01）, illustrate that the mouse cough that Medications Example 4 of the present invention induces to strong aqua ammonia has cough-relieving to make
With.
2nd, the expectorant test of Medications Example 4 of the present invention：Take SD rat 50, male and female half and half, be randomly divided into 5 groups, every group
10, i.e. blank control group, to isometric(al) distilled water；Positive controls, to ammonium chloride lg/kg.d-l；Medications Example of the present invention
4 high, medium and low dosage groups, give Medications Example 4 medicine 6g, 3g, 1.5g crude drug/kg.d of the present invention respectively-l.Before experiment, fasting is not
After prohibiting water 8～12h, 10% chloral hydrate 0.35g/kg, after intraperitoneal injection of anesthesia, rat dorsal positions are fixed on surgical plate, cervical region
Sterilized with 75% cotton ball soaked in alcohol, the otch of medisection about 1cm length, finds trachea, in trachea thyroid cartilage lower edge sharp needles
Head pricks an aperture, subsequently the capillary tube of 0.5mm is inserted trachea, to just contacting trachea.Sputum is drawn with capillary tube long
Degree, as the expectorant effect of evaluation medicine, when putting sputum in capillary tube and being full of, separately changes one immediately.Record administration before 2h just
Often after secretory volume, continue to observe 2h sputum secretory volume again after duodenal administration.Relatively administration forward backward averaging is secreted per hour
Sputum secretory volume, and take statistics learning analysis.The results are shown in Table 2.
The phlegm-dispelling functions (x ± s, n=10) to rat for table 2 Medications Example 4 of the present invention
Before Group Animals number dosage (g/kg) administration（cm/h）After administration（cm/h）Difference（cm/h）
Blank control group 10 isometric(al) 3.75 ± 0.54 4.65 ± 1.32 0.54 ± 0.88
Positive controls 10 1.0 3.63 ± 0.48 9.98 ± 2.54 5.36 ± 2.33**
Low dose group 10 1.5 3.62 ± 0.76 5.76 ± 1.37 2.54 ± 1.44*
Middle dose group 10 3 3.56 ± 0.83 8.06 ± 1.82 2.96 ± 1.66**
High dose group 10 6 3.47 ± 0.69 9.74 ± 2.33 4.69 ± 2.47**
Explanation：Compare with blank control group:*P<0.05；**P<0.0l.
As seen from Table 2：Medications Example 4 of the present invention can be effectively increased rat trachea sputum secretory volume, with blank control group
Relatively, the expectoration amount high, middle dosage can significantly increase rat（P<0.01）.
3rd, the test of relievining asthma of Medications Example 4 of the present invention：Cavia porcelluss are placed in 4000mL clear glass bell jar, 0.2%
Histamine phosphate solution ultrasonic atomizatio gives 15s, the asthmatic latent period of observed and recorded Cavia porcelluss（Start to asthma attack from spraying, go out
Existing dyspnea, until twitch the time fallen）If more than 150s nonresponder, not selecting.Take the qualified Cavia porcelluss 50 of screening
Only, male and female half and half, are randomly divided into 5 groups, every group 10.I.e. blank control group, to isometric(al) distilled water；Positive controls, to half
Summer cough syrup 5.5ml/kg.d-l；The high, medium and low dosage group of Medications Example 4 of the present invention, gives Medications Example 4 of the present invention respectively
Medicine 6g, 3g, 1.5g crude drug/kg.d-l.The equal gastric infusion of each group, 1 time/d, continuous 7d.After last dose 1h, Cavia porcelluss are put people
The asthmatic latent period of Cavia porcelluss in 4000mL clear glass bell jar, is measured by preselected conditions and method.If still not occurring more than 6min
Asthma reaction person, presses 360s its incubation period and calculates.The results are shown in Table 3.
The antiasthmatic effect (x ± s, n=10) to Cavia porcelluss for table 3 Medications Example 4 of the present invention
Group Animals number dosage (g/kg) asthma hides (s)
Blank control group 10 66.6 ± 32.07
Positive controls 10 5.5ml/Kg 114.2 ± 56.86
Low dose group 10 1.5 132.7 ± 79.44
Middle dose group 10 3 157.8 ± 65.33*
High dose group 10 6 189.4 ± 41.46*
Explanation：Compare with model control group：*P<0.05.
As seen from Table 3：Medications Example 4 of the present invention can suppress the Experimental Asthma In Guinea-pigs caused by histamine phosphate.With blank control group
Relatively, high, middle dose group Cavia porcelluss asthmatic latent period extends, and has significant difference（P<0.05）.
4th, the anti-inflammation test of Medications Example 4 of the present invention：Take mice 50, male and female half and half, be randomly divided into 5 groups, every group 10
Only.I.e. negative control group, to isometric(al) distilled water；Positive controls, to prednisone acetate tablets 12mg/kg.d-l；Medicine of the present invention
The high, medium and low dosage group of embodiment 4, gives Medications Example 4 medicine 10g, 5g, 2.5g crude drug/kg.d of the present invention respectively-l.Each group is all
Gastric infusion, 1 time/d, continuous 7d.After last dose 60min, every Mus auris dextra applies dimethylbenzene 20 l and causes inflammation, locates after causing scorching 30min
Dead mice, takes off bilateral auricle with the card punch of diameter 6mm（Take symmetric position）, claim its quality respectively, with two auricle quality it
Difference, as swelling, calculates suppression ratio.The results are shown in Table 4.
Table 4 Medications Example 4 xylol of the present invention causes the impact (x ± s, n=10) of mice ear
Group Animals number dosage (g/kg) swelling (mg)
Blank control group 10 14.58 ± 2.68
Positive controls 10 12mg/Kg 5.83 ± 2.44**
Low dose group 10 2.5 10.13 ± 4.67
Middle dose group 10 5 12.63 ± 3.76
High dose group 10 10 8.78 ± 3.35*
Explanation：Compare with model control group：*P<0.05；**P<0.0l.
As seen from Table 4：Medications Example 4 of the present invention can suppress the mice ear caused by dimethylbenzene, with blank control group
Relatively, low dosage has significant difference（P<0.05）, illustrate that Medications Example 4 of the present invention has to the acute inflammation of mice certain
Inhibitory action.
【Test example 2】Medications Example 4 of the present invention treats the clinical observation on the therapeutic effect of exogenous cough：
Physical data：Totally 200 observation patients, man 106, female 94, the oldest 82 years old, minimum 7 years old, the mean age 48
In year, onset is in the majority in 4 days, and average 2 days, morbidity season was many with Winter-Spring.It is randomly divided into two groups by digital method, treatment group 100
Example, man 52, female 48,48.4 years old mean age；Matched group 100, man 54, female 46,49.3 years old mean age.Two groups
The age of case, sex and physical data no significant difference.
Diagnostic criteria：With reference in August, 1999 version《Chinese Internal Medicine》The cough clinical assessment scale that teaching material is formulated.1. to cough
Cough, cough up phlegm as cardinal symptom.Onset is anxious, can be with fever with aversion to cold symptom.2. double pulmonary respiration sounds are coarse, or audible dry and wet rale,
3. total white blood cellses or neutrophilic granulocyte increase, and conducting lung X-ray examination is normal or texture increases slightly.
Therapeutic Method：1st, matched group：Regular western medicine treatment：Bromhexine hydrochloride, mucosolvan, antibiotic, Supporting Therapy of suiting the medicine to the illness, 3 days
For a course for the treatment of.
2nd, treatment group：On the basis for the treatment of of control group, using Medications Example 4 of the present invention, a 1.2～2g, one day 2
～3 times.
Clinical efficacy evaluation criteria：With reference to State Administration of Traditional Chinese Medicine《Chinese medical disease Standardization of diagnosis and curative effect》Cough disease is treated
Effect standard formulation.Cure：Cough and clinical sign disappear.Take a turn for the better：Cough mitigates, and the amount of coughing up phlegm is few.Do not heal：Symptom no substantially changes
Become.
Controlling takes a turn for the better further adds up to total effective rate.
Clinical observation result is shown in Table 5.
5 liang of group Clinical efficacy comparisons of table（Example, %）
Group number of cases cures the total effective rate of not healing that takes a turn for the better
Treatment group 100 59 38 3 97*
Matched group 100 43 48 9 91
Note：Compare with matched group*P<0.05.
Clinical observation result shows：Medications Example 4 of the present invention treats exogenous cough's determined curative effect, and clinic is promoted and made
With having certain application prospect.
Claims (5)
1. a kind of medicine with relieving cough and resolving phlegm effect is it is characterised in that it is to be made up of active component or by active component
Make with pharmaceutically acceptable adjuvant, wherein said active component is made up of the crude drug of following concrete weight：Sandwort
35～105g, Eriophyton wallichii Benth 30～90g, the Flos rosae multiflorae 20～60g, Radix phlomidis younghusbandii 40～120g, hide Radix Asteriss 35～105g, Herba Trigonellae Ruthenicae 20～
60g, Radix Glycyrrhizae 10～30g, the Radix Aucklandiae 10～30g, Fructus Hippophae extractum 10～30g, Fructus Chebulae 25～75g.
2. medicine according to claim 1, wherein said active component is made up of the crude drug of following concrete weight：
Sandwort 56～84g, Eriophyton wallichii Benth 48～72g, the Flos rosae multiflorae 32～48g, Radix phlomidis younghusbandii 64～96g, hide Radix Asteriss 56～84g, Herba Trigonellae Ruthenicae 32～
48g, Radix Glycyrrhizae 16～24g, the Radix Aucklandiae 16～24g, Fructus Hippophae extractum 16～24g, Fructus Chebulae 40～60g.
3. medicine according to claim 2, wherein said active component is made up of the crude drug of following concrete weight：
Sandwort 70g, Eriophyton wallichii Benth 60g, Flos rosae multiflorae 40g, Radix phlomidis younghusbandii 80g, Tibetan Radix Asteriss 70g, Herba Trigonellae Ruthenicae 40g, Radix Glycyrrhizae 20g, Radix Aucklandiae 20g, Fructus Hippophae
Cream 20g, Fructus Chebulae 50g.
4. the medicine according to any one of claim 13, it is peroral dosage form.
5. medicine according to claim 4, it is decoction pulvis, medicinal tea, powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611028907.4A CN106389589A (en) | 2016-11-22 | 2016-11-22 | Medicine with effect of relieving cough and reducing sputum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611028907.4A CN106389589A (en) | 2016-11-22 | 2016-11-22 | Medicine with effect of relieving cough and reducing sputum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106389589A true CN106389589A (en) | 2017-02-15 |
Family
ID=58081602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611028907.4A Withdrawn CN106389589A (en) | 2016-11-22 | 2016-11-22 | Medicine with effect of relieving cough and reducing sputum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389589A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110721295A (en) * | 2019-08-13 | 2020-01-24 | 浙江海洋大学 | Preparation method of solid granules with inflammation diminishing and cough relieving functions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813801A (en) * | 2012-09-14 | 2012-12-12 | 措尼 | Traditional Tibetan medicine for treating cough and preparation method thereof |
| CN103330767A (en) * | 2013-07-17 | 2013-10-02 | 宋永心 | Tibetan medicine for curing cough and preparing method thereof |
-
2016
- 2016-11-22 CN CN201611028907.4A patent/CN106389589A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813801A (en) * | 2012-09-14 | 2012-12-12 | 措尼 | Traditional Tibetan medicine for treating cough and preparation method thereof |
| CN103330767A (en) * | 2013-07-17 | 2013-10-02 | 宋永心 | Tibetan medicine for curing cough and preparing method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110721295A (en) * | 2019-08-13 | 2020-01-24 | 浙江海洋大学 | Preparation method of solid granules with inflammation diminishing and cough relieving functions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102813801B (en) | Traditional Tibetan medicine for treating cough and preparation method thereof | |
| CN103099948A (en) | Pharmaceutical composition for treating pharyngitis and preparation method | |
| CN103340932A (en) | Tibetan medicine for treating chronic bronchitis and preparation method thereof | |
| CN104324125B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CN103330767B (en) | Tibetan medicine for curing cough and preparing method thereof | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN106389589A (en) | Medicine with effect of relieving cough and reducing sputum | |
| CN111358906B (en) | Traditional Chinese medicine composition suitable for exogenous diseases | |
| CN113616721A (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN105998840A (en) | External use ointment used for treating insect bite dermatitis and preparation method | |
| CN104840737A (en) | Traditional Chinese medicine composition with qi invigorating and lung moistening functions and preparation method and application thereof | |
| CN106389590A (en) | Preparation method of medicine with effect of relieving cough and reducing sputum | |
| CN102058770B (en) | Traditional Chinese medicinal composition for clearing lung, resolving phlegm and relieving cough and asthma and preparation method thereof | |
| CN105288195A (en) | Medicine for treating thyroiditis and preparation method for medicine | |
| CN106361924A (en) | Pharynx clearing and throat relieving medicine | |
| CN104667247A (en) | Traditional Chinese medicinal composition for treating cough and preparation method of traditional Chinese medicinal composition | |
| CN105288157A (en) | Traditional Chinese medicine composition with effects of freeing lung and relieving asthma, preparation method and application thereof | |
| CN106309801A (en) | Preparation method for pharmaceutical with throat clearing efficacy | |
| CN104667049A (en) | Traditional Chinese medicine preparation for treating pneumonia and preparation method of traditional Chinese medicine preparation | |
| CN104258231A (en) | Traditional Chinese medicine composition for treating cough | |
| CN104107357A (en) | Granule with functions of relieving cough and reducing sputum and preparation method thereof | |
| CN104055886A (en) | Medicinal composition for treating chronic cough, and preparation method and application thereof | |
| CN103599341B (en) | A kind of pharmaceutical composition for the treatment of cough with asthma | |
| CN103623389A (en) | Traditional Chinese medicinal composition for treating wind-cold type pediatric bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170215 |